Andreas Greinacher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1601957/publications.pdf

Version: 2024-02-01

		2669	5101
484	35,121	95	166
papers	citations	h-index	g-index

514	514	514	24165
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine, 2021, 384, 2092-2101.	13.9	1,765
2	Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. Journal of Thrombosis and Haemostasis, 2006, 4, 759-765.	1.9	916
3	Treatment and Prevention of Heparin-Induced Thrombocytopenia. Chest, 2008, 133, 340S-380S.	0.4	783
4	Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention. Chest, 2004, 126, 311S-337S.	0.4	766
5	Heparin-induced thrombocytopenia and cardiac surgery. Annals of Thoracic Surgery, 2003, 76, 2121-2131.	0.7	638
6	Heparin-induced Thrombocytopenia: Towards Consensus. Thrombosis and Haemostasis, 1998, 79, 1-7.	1.8	595
7	Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia. Circulation, 1999, 99, 73-80.	1.6	505
8	Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2015, 373, 252-261.	13.9	492
9	A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nature Genetics, 2009, 41, 1182-1190.	9.4	481
10	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances, 2018, 2, 3360-3392.	2.5	448
11	New gene functions in megakaryopoiesis and platelet formation. Nature, 2011, 480, 201-208.	13.7	401
12	The Polygenic and Monogenic Basis of Blood Traits and Diseases. Cell, 2020, 182, 1214-1231.e11.	13.5	388
13	Common Variants at 10 Genomic Loci Influence Hemoglobin A1C Levels via Glycemic and Nonglycemic Pathways. Diabetes, 2010, 59, 3229-3239.	0.3	387
14	Lepirudin (Recombinant Hirudin) for Parenteral Anticoagulation in Patients With Heparin-Induced Thrombocytopenia. Circulation, 1999, 100, 587-593.	1.6	360
15	Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. Cell, 2020, 182, 1198-1213.e14.	13.5	353
16	Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. Thrombosis and Haemostasis, 2005, 94, 132-135.	1.8	352
17	A Rapid and Sensitive Test for Diagnosing Heparin-Associated Thrombocytopenia. Thrombosis and Haemostasis, 1991, 66, 734-736.	1.8	345
18	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. American Journal of Human Genetics, 2017, 100, 75-90.	2.6	343

#	Article	IF	Citations
19	Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102.	13.7	338
20	Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thrombosis and Haemostasis, 1994, 71, 247-51.	1.8	336
21	Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood, 2000, 96, 846-851.	0.6	335
22	Antibodies to Platelet Factor 4â€“Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight Heparin. Circulation, 1999, 99, 2530-2536.	1.6	325
23	Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nature Genetics, 2009, 41, 1191-1198.	9.4	324
24	Seventy-five genetic loci influencing the human red blood cell. Nature, 2012, 492, 369-375.	13.7	320
25	Autoimmune heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2017, 15, 2099-2114.	1.9	319
26	Antigen Generation in Heparin-Associated Thrombocytopenia: The Nonimmunologic Type and the Immunologic Type Are Closely Linked in Their Pathogenesis. Seminars in Thrombosis and Hemostasis, 1995, 21, 106-116.	1.5	302
27	Nonmuscle Myosin Heavy Chain IIA Mutations Define a Spectrum of Autosomal Dominant Macrothrombocytopenias: May-Hegglin Anomaly and Fechtner, Sebastian, Epstein, and Alport-Like Syndromes. American Journal of Human Genetics, 2001, 69, 1033-1045.	2.6	283
28	Antiâ€“platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood, 2005, 106, 3791-3796.	0.6	271
29	Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion, 1994, 34, 381-385.	0.8	268
30	Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood, 2006, 108, 2937-2941.	0.6	259
31	Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood, 2021, 138, 2256-2268.	0.6	228
32	Anaphylactic and Anaphylactoid Reactions Associated With Lepirudin in Patients With Heparin-Induced Thrombocytopenia. Circulation, 2003, 108, 2062-2065.	1.6	224
33	Heparinâ€induced thrombocytopenia: a prospective study on the incidence, plateletâ€activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. Journal of Thrombosis and Haemostasis, 2007, 5, 1666-1673.	1.9	224
34	Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood, 2000, 96, 2373-2378.	0.6	220
35	Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. Journal of Thrombosis and Haemostasis, 2005, 3, 2428-2436.	1.9	216
36	Bivalirudin. Thrombosis and Haemostasis, 2008, 99, 830-839.	1.8	211

#	Article	IF	Citations
37	The direct thrombin inhibitor hirudin. Thrombosis and Haemostasis, 2008, 99, 819-829.	1.8	207
38	Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood, 2011, 117, 1370-1378.	0.6	207
39	Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood, 2005, 105, 139-144.	0.6	196
40	Heparin-Associated Thrombocytopenia: The Antibody Is Not Heparin Specific. Thrombosis and Haemostasis, 1992, 67, 545-549.	1.8	192
41	Induction of monocyte tissue factor expression by antibodies to heparinâ€“platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood, 2001, 97, 3300-3302.	0.6	191
42	Heparin-Induced Thrombocytopenia. Chest, 2002, 122, 37-42.	0.4	189
43	Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH. Hamostaseologie, 2021, 41, 184-189.	0.9	189
44	Decision Analysis for Use of Platelet Aggregation Test, Carbon 14â€“Serotonin Release Assay, and Heparinâ€“Platelet Factor 4 Enzyme-Linked Immunosorbent Assay for Diagnosis of Heparin-Induced Thrombocytopenia. American Journal of Clinical Pathology, 1999, 111, 700-706.	0.4	187
45	Heparin-induced thrombocytopenia and cardiac surgery. Annals of Thoracic Surgery, 2003, 76, 638-648.	0.7	187
46	MYH9-Related Platelet Disorders. Seminars in Thrombosis and Hemostasis, 2009, 35, 189-203.	1.5	187
47	The îœ€2 Gene Coding Sequence T807/A873 of the Platelet Collagen Receptor Integrin îœ€2Î²1 Might Be a Genetic Risk Factor for the Development of Stroke in Younger Patients. Blood, 1999, 93, 3583-3586.	0.6	186
48	A Comparison of Danaparoid and Lepirudin in Heparin-induced Thrombocytopenia. Thrombosis and Haemostasis, 2001, 85, 950-957.	1.8	186
49	Heparin-induced thrombocytopenia in intensive care patients. Critical Care Medicine, 2007, 35, 1165-1176.	0.4	179
50	Heparin-Induced Thrombocytopenia: New Insights Into the Impact of the FcÎ³RIIa-R-H131 Polymorphism. Blood, 1998, 92, 1526-1531.	0.6	176
51	Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood, 2000, 96, 846-851.	0.6	175
52	Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. British Journal of Haematology, 2005, 128, 837-841.	1.2	172
53	Anucleate platelets generate progeny. Blood, 2010, 115, 3801-3809.	0.6	164
54	The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood, 2004, 104, 3603-3610.	0.6	163

#	Article	IF	Citations
55	Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. European Journal of Haematology, 2006, 76, 420-426.	1.1	162
56	First Workshop for Detection of Heparin-induced Antibodies: Validation of the Heparin-induced Platelet-activation Test (HIPA) in Comparison with a PF4/Heparin ELISA. Thrombosis and Haemostasis, 1999, 81, 625-629.	1.8	161
57	Monitoring of r-Hirudin Anticoagulation during Cardiopulmonary Bypass â€“ Assessment of the Whole Blood Ecarin Clotting Time. Thrombosis and Haemostasis, 1997, 77, 0920-0925.	1.8	158
58	The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood, 2010, 115, 1797-1803.	0.6	157
59	Earlyâ€onset and persisting thrombocytopenia in postâ€cardiac surgery patients is rarely due to heparinâ€induced thrombocytopenia, even when antibody tests are positive. Journal of Thrombosis and Haemostasis, 2010, 8, 30-36.	1.9	157
60	Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2386-2393.	1.1	156
61	Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood, 2006, 107, 3761-3763.	0.6	152
62	Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. Journal of Thrombosis and Haemostasis, 2011, 9, 2498-2500.	1.9	150
63	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 2020, 583, 90-95.	13.7	148
64	Recombinant Hirudin in Clinical Practice. Circulation, 2001, 103, 1479-1484.	1.6	145
65	Characterization of the human neutrophil alloantigen-3a. Nature Medicine, 2010, 16, 45-48.	15.2	143
66	Reversal of anticoagulants: an overview of current developments. Thrombosis and Haemostasis, 2015, 113, 931-942.	1.8	142
67	Thrombocytopenia in the Intensive Care Unit Patient. Hematology American Society of Hematology Education Program, 2010, 2010, 135-143.	0.9	140
68	Characterization of the Structural Requirements for a Carbohydrate Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-associated Thrombocytopenia. Thrombosis and Haemostasis, 1995, 74, 886-892.	1.8	139
69	BLOOD COMPONENTS: A novel approach to pathogen reduction in platelet concentrates using shortâ€wave ultraviolet light. Transfusion, 2009, 49, 2612-2624.	0.8	138
70	Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood, 2004, 104, 3072-3077.	0.6	134
71	Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet, The, 2011, 378, 1166-1173.	6.3	134
72	Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thrombosis and Haemostasis, 2005, 94, 958-964.	1.8	130

#	Article	IF	Citations
73	Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood, 2013, 122, 272-281.	0.6	129
74	Heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2009, 7, 9-12.	1.9	126
75	Amplification of bacteria-induced platelet activation is triggered by FcÎ³RIIA, integrin Î±IIbÎ²3, and platelet factor 4. Blood, 2014, 123, 3166-3174.	0.6	126
76	Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood, 2021, 138, 299-303.	0.6	125
77	<scp>COVID</scp>â€19 Vaccineâ€Associated Cerebral Venous Thrombosis in Germany. Annals of Neurology, 2021, 90, 627-639.	2.8	122
78	egc -Encoded Superantigens from Staphylococcus aureus Are Neutralized by Human Sera Much Less Efficiently than Are Classical Staphylococcal Enterotoxins or Toxic Shock Syndrome Toxin. Infection and Immunity, 2004, 72, 4061-4071.	1.0	118
79	Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Critical Care, 2020, 24, 364.	2.5	118
80	The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. Journal of Critical Care, 2010, 25, 287-293.	1.0	117
81	Recognition, treatment, and prevention of heparin-induced thrombocytopenia: Review and update. Thrombosis Research, 2006, 118, 165-176.	0.8	116
82	Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. Nature Genetics, 2014, 46, 629-634.	9.4	113
83	Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
84	The temporal profile of the anti-PF4/heparin immune response. Blood, 2009, 113, 4970-4976.	0.6	109
85	Multiple Loci Are Associated with White Blood Cell Phenotypes. PLoS Genetics, 2011, 7, e1002113.	1.5	106
86	Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thrombosis Research, 2008, 122, 211-220.	0.8	105
87	A Genome-wide Association Study Identifies Three Loci Associated with Mean Platelet Volume. American Journal of Human Genetics, 2009, 84, 66-71.	2.6	104
88	Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood, 2000, 96, 846-51.	0.6	104
89	Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thrombosis and Haemostasis, 2004, 91, 719-724.	1.8	103
90	Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood, 2006, 108, 1492-1496.	0.6	103

#	Article	IF	Citations
91	Profiling of alterations in platelet proteins during storage of platelet concentrates. Transfusion, 2007, 47, 1221-1233.	0.8	103
92	Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood, 2012, 119, 1248-1255.	0.6	103
93	Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood, 2015, 125, 1180-1188.	0.6	102
94	Antiâ€“platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood, 2021, 138, 1269-1277.	0.6	102
95	Adenosine Diphosphate (ADP) and ADP Receptor Play a Major Role in Platelet Activation/Aggregation Induced by Sera From Heparin-Induced Thrombocytopenia Patients. Blood, 1998, 91, 549-554.	0.6	99
96	Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood, 2012, 120, 3345-3352.	0.6	99
97	Staphylococcus aureusCarriers Neutralize Superantigens by Antibodies Specific for Their Colonizing Strain: A Potential Explanation for Their Improved Prognosis in Severe Sepsis. Journal of Infectious Diseases, 2006, 193, 1275-1278.	1.9	98
98	Polymorphisms of the Human Platelet Antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the Platelet Receptors for Fibrinogen (GPIIb/IIIa), von Willebrand Factor (GPIb/IX), and Collagen (GPIa/IIa) Are Not Correlated With an Increased Risk for Stroke. Stroke, 1997, 28, 1392-1395.	1.0	96
99	Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opinion on Drug Safety, 2009, 8, 129-144.	1.0	95
100	Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. British Journal of Haematology, 2003, 121, 786-792.	1.2	94
101	Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood, 2005, 106, 2921-2922.	0.6	94
102	Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood, 2011, 118, 1395-1401.	0.6	93
103	Implications of demographics on future blood supply: a populationâ€based crossâ€sectional study. Transfusion, 2011, 51, 702-709.	0.8	92
104	Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood, 2017, 129, 1538-1547.	0.6	91
105	PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia. New England Journal of Medicine, 2021, 385, 376-378.	13.9	91
106	Sebastian platelet syndrome: A new variant of hereditary macrothrombocytopenia with leukocyte inclusions. Blut, 1990, 61, 282-288.	1.2	90
107	Falseâ€positive tests for heparinâ€induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. Journal of Thrombosis and Haemostasis, 2009, 7, 1070-1074.	1.9	89
108	Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity. Nature Communications, 2017, 8, 14945.	5.8	89

#	Article	IF	Citations
109	Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. British Journal of Haematology, 1993, 84, 711-716.	1.2	86
110	Pregnancy complicated by heparin associated thrombocytopenia: Management by a prospectively in vitro selected heparinoid (ORG 10172). Thrombosis Research, 1993, 71, 123-126.	0.8	85
111	The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. British Journal of Haematology, 2002, 116, 887-891.	1.2	85
112	Transporters in human platelets: physiologic function and impact for pharmacotherapy. Blood, 2012, 119, 3394-3402.	0.6	84
113	Heparin-induced thrombocytopenia: towards consensus. Thrombosis and Haemostasis, 1998, 79, 1-7.	1.8	84
114	Fucosyltransferase 2 (FUT2) non-secretor status and blood group B are associated with elevated serum lipase activity in asymptomatic subjects, and an increased risk for chronic pancreatitis: a genetic association study. Gut, 2015, 64, 646-656.	6.1	82
115	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. American Journal of Human Genetics, 2016, 99, 40-55.	2.6	82
116	Proteome Changes in Platelets After Pathogen Inactivationâ€"An Interlaboratory Consensus. Transfusion Medicine Reviews, 2014, 28, 72-83.	0.9	80
117	Vaccine-Induced Thrombocytopenia with Severe Headache. New England Journal of Medicine, 2021, 385, 2103-2105.	13.9	79
118	Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2015, 373, 1882-1884.	13.9	78
119	Increased risk of thrombosis in FcÎ³RIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. Blood, 2015, 125, 2397-2404.	0.6	77
120	Demographic Changes: The Impact for Safe Blood Supply. Transfusion Medicine and Hemotherapy, 2010, 37, 141-148.	0.7	76
121	Vaccineâ€induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. Journal of Thrombosis and Haemostasis, 2022, 20, 149-156.	1.9	76
122	Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. British Journal of Haematology, 1992, 81, 252-254.	1.2	75
123	Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. Journal of Thrombosis and Haemostasis, 2008, 6, 428-435.	1.9	74
124	Heparinâ€induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. Journal of Thrombosis and Haemostasis, 2010, 8, 2025-2031.	1.9	74
125	A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. Human Molecular Genetics, 2016, 25, 358-370.	1.4	73
126	Heparin-induced thrombocytopenia in paediatric patients â€“ a review of the literature and a new case treated with danaparoid sodium. European Journal of Pediatrics, 1999, 158, S130-S133.	1.3	72

#	Article	IF	Citations
127	Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: a placebo-controlled trial. Journal of Pediatrics, 2003, 143, 741-745.	0.9	72
128	Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 1373-1381.e4.	0.4	72
129	Heparin-Induced Thrombocytopenia in Patients with Ventricular Assist Devices: Are New Prevention Strategies Required?. Annals of Thoracic Surgery, 2009, 87, 1633-1640.	0.7	72
130	An open conformation of ADAMTSâ€13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2018, 16, 378-388.	1.9	72
131	Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. Thrombosis Research, 2021, 204, 40-51.	0.8	72
132	Diagnosis of inherited platelet disorders on a blood smear: a tool to facilitate worldwide diagnosis of platelet disorders. Journal of Thrombosis and Haemostasis, 2017, 15, 1511-1521.	1.9	71
133	Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia. Journal of Clinical Medicine, 2020, 9, 2212.	1.0	71
134	Very Low Platelet Counts in Post-transfusion Purpura Falsely Diagnosed as Heparin-induced Thrombocytopenia. Thrombosis Research, 2000, 100, 115-125.	0.8	70
135	Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34 ⁺ progenitors. Haematologica, 2017, 102, 282-294.	1.7	70
136	Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thrombosis Research, 2013, 131, e85-e90.	0.8	69
137	Heparinâ€induced thrombocytopenia â€“ therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4â€“heparin complexes. Journal of Thrombosis and Haemostasis, 2008, 6, 2160-2167.	1.9	68
138	Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy â€“ A European Perspective. Thrombosis Research, 2012, 129, 426-433.	0.8	68
139	A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thrombosis and Haemostasis, 1991, 66, 734-6.	1.8	68
140	Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. Thrombosis and Haemostasis, 2014, 112, 53-64.	1.8	67
141	Binding of antiâ€platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood, 2014, 124, 2442-2449.	0.6	67
142	Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thrombosis Research, 2006, 117, 507-515.	0.8	66
143	FcÎ³Receptors IIa on Cardiomyocytes and Their Potential Functional Relevance in Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2007, 49, 1684-1692.	1.2	66
144	Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood, 2003, 101, 2617-2619.	0.6	65

#	Article	IF	Citations
145	Antiâ€“protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. Blood, 2013, 121, 2821-2827.	0.6	64
146	Platelets kill bacteria by bridging innate and adaptive immunity via platelet factor 4 and FcÎ³RIIA. Journal of Thrombosis and Haemostasis, 2018, 16, 1187-1197.	1.9	64
147	Genoâ€•and phenotyping and immunogenicity of HNAâ€3. Transfusion, 2011, 51, 18-24.	0.8	63
148	Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a singleâ€center prospective study in highâ€risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion, 2011, 51, 2620-2626.	0.8	63
149	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. Haematologica, 2014, 99, 1387-1394.	1.7	63
150	Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. Journal of Thrombosis and Haemostasis, 2006, 4, 678-679.	1.9	62
151	How I evaluate and treat thrombocytopenia in the intensive care unit patient. Blood, 2016, 128, 3032-3042.	0.6	62
152	COVIDâ€19 patients often show highâ€titer nonâ€plateletâ€activating antiâ€PF4/heparin IgG antibodies. Journal of Thrombosis and Haemostasis, 2021, 19, 1294-1298.	1.9	62
153	IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. Journal of Thrombosis and Haemostasis, 2007, 5, 235-241.	1.9	61
154	MYH-9 Related Platelet Disorders: Strategies for Management and Diagnosis. Transfusion Medicine and Hemotherapy, 2010, 37, 5-5.	0.7	61
155	Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidenceâ€based practice, an international approach. British Journal of Haematology, 2019, 185, 549-562.	1.2	61
156	Hereditary types of thrombocytopenia with giant platelets and inclusion bodies in the leukocytes. Blut, 1990, 60, 53-60.	1.2	60
157	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. American Journal of Human Genetics, 2016, 99, 8-21.	2.6	60
158	Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for Atorvastatin. Drug Metabolism and Disposition, 2009, 37, 1129-1137.	1.7	59
159	Severe and persistent heparinâ€induced thrombocytopenia despite fondaparinux treatment. American Journal of Hematology, 2015, 90, 675-678.	2.0	59
160	Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood, 2008, 112, 4024-4027.	0.6	58
161	The Non-Hemostatic Aspects of Transfused Platelets. Frontiers in Medicine, 2018, 5, 42.	1.2	57
162	Decline in Pathogenic Antibodies over Time in VITT. New England Journal of Medicine, 2021, 385, 1815-1816.	13.9	56

#	Article	IF	Citations
163	Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood, 2004, 103, 613-616.	0.6	55
164	Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF. Blood, 2015, 126, e19-e29.	0.6	55
165	Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. International Journal of Cancer, 2009, 124, 2303-2311.	2.3	54
166	Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia. Chest, 2021, 159, 2417-2427.	0.4	54
167	Effectiveness of a new immuno-assay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thrombosis and Haemostasis, 2010, 103, 145-150.	1.8	53
168	Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion, 2004, 44, 1033-1040.	0.8	52
169	Polymorphisms of protein tyrosine phosphatase CD148 influence FcÎ³RIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. Blood, 2012, 120, 1309-1316.	0.6	52
170	Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants. Anesthesiology, 2017, 127, 111-120.	1.3	52
171	Emergency transfusion of patients with unknown blood type with blood group O Rhesus D positive red blood cell concentrates: a prospective, single-centre, observational study. Lancet Haematology,the, 2017, 4, e218-e224.	2.2	52
172	A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. Blood, 2021, 137, 3656-3659.	0.6	52
173	Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thrombosis Research, 2021, 203, 163-171.	0.8	52
174	Antiâ€PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of nonâ€drug risk factors and evidence for a stoichiometryâ€based model of immunization. Journal of Thrombosis and Haemostasis, 2010, 8, 504-512.	1.9	51
175	Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparinâ€induced thrombocytopenia antibodies. British Journal of Haematology, 2017, 179, 811-819.	1.2	51
176	Non-muscle myosin IIA is required for the development of the zebrafish glomerulus. Kidney International, 2011, 80, 1055-1063.	2.6	50
177	Risk factors for heparin-induced thrombocytopenia: Focus on FcÎ³ receptors. Thrombosis and Haemostasis, 2016, 116, 799-805.	1.8	50
178	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. American Journal of Human Genetics, 2016, 99, 22-39.	2.6	50
179	DRUG-INDUCED AND DRUG-DEPENDENT IMMUNE THROMBOCYTOPENIAS. Reviews in Clinical and Experimental Hematology, 2001, 5, 166-200.	0.1	49
180	A genome-wide association study of heparin-induced thrombocyto - penia using an electronic medical record. Thrombosis and Haemostasis, 2015, 113, 772-781.	1.8	49

#	Article	IF	Citations
181	A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. European Journal of Cardio-thoracic Surgery, 1996, 10, 386-388.	0.6	48
182	Autosomal-dominant giant platelet syndromes: a hint of the same genetic defect as in Fechtner syndrome owing to a similar genetic linkage to chromosome 22q11-13. Blood, 2000, 96, 3447-3451.	0.6	47
183	Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated antiâ€“HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia. Blood, 2013, 122, 321-327.	0.6	47
184	Current insights into the laboratory diagnosis of HIT. International Journal of Laboratory Hematology, 2014, 36, 296-305.	0.7	47
185	Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds. Nanoscale, 2015, 7, 10130-10139.	2.8	46
186	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. American Journal of Human Genetics, 2018, 103, 3-18.	2.6	46
187	Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time. Thrombosis and Haemostasis, 1997, 77, 920-5.	1.8	46
188	Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood, 2000, 96, 2373-8.	0.6	46
189	Role of MRP4 (ABCC4) in Platelet Adenine Nucleotide-Storage. American Journal of Pathology, 2010, 176, 1097-1103.	1.9	45
190	Rupture Forces among Human Blood Platelets at different Degrees of Activation. Scientific Reports, 2016, 6, 25402.	1.6	45
191	Diagnosis and management of heparin-induced thrombocytopenia. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 291-310.	0.6	45
192	Developments in the definition and clinical impact of human neutrophil antigens. Current Opinion in Hematology, 2011, 18, 452-460.	1.2	44
193	A population-based longitudinal study on the implication of demographic changes on blood donation and transfusion demand. Blood Advances, 2017, 1, 867-874.	2.5	44
194	Incidence and clinical relevance of antiâ€“platelet factor 4/heparin antibodies before cardiac surgery. American Heart Journal, 2010, 160, 362-369.	1.2	43
195	Thrombocytopenia in the Intensive Care Unitâ€”Diagnostic Approach and Management. Seminars in Hematology, 2013, 50, 239-250.	1.8	43
196	Polyphosphates form antigenic complexes with platelet factor 4 (PF4) and enhance PF4-binding to bacteria. Thrombosis and Haemostasis, 2015, 114, 1189-1198.	1.8	42
197	FcÎ³-Receptor IIa Polymorphism and the Role of Immunoadsorption in Cardiac Dysfunction in Patients With Dilated Cardiomyopathy. Clinical Pharmacology and Therapeutics, 2010, 87, 452-458.	2.3	41
198	Platelet Transfusion in Hematology, Oncology and Surgery. Deutsches Ärzteblatt International, 2014, 111, 809-15.	0.6	41

#	Article	IF	Citations
199	Role of Platelet Size Revisitedâ€"Function and Protein Composition of Large and Small Platelets. Thrombosis and Haemostasis, 2019, 119, 407-420.	1.8	41
200	Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. Expert Review of Cardiovascular Therapy, 2004, 2, 339-357.	0.6	40
201	Treatment of Heparin-Induced Thrombocytopenia. Thrombosis and Haemostasis, 1999, 82, 457-467.	1.8	40
202	Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration. Blood, 2022, 140, 478-490.	0.6	40
203	Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. Therapeutic Advances in Hematology, 2012, 3, 237-251.	1.1	39
204	Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood, 2009, 114, 1250-1253.	0.6	38
205	Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. International Journal of Legal Medicine, 2021, 135, 2335-2345.	1.2	38
206	Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thrombosis and Haemostasis, 1992, 67, 545-9.	1.8	38
207	Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thrombosis Research, 1996, 81, 641-649.	0.8	37
208	Proteomics of Blood-Based Therapeutics. BioDrugs, 2007, 21, 179-193.	2.2	37
209	Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates. Haematologica, 2019, 104, 207-214.	1.7	37
210	Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology, 2021, 268, 4483-4485.	1.8	37
211	Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. Haematologica, 2022, 107, 947-957.	1.7	37
212	Structural Requirements for the Procoagulant Activity of Nucleic Acids. PLoS ONE, 2012, 7, e50399.	1.1	36
213	Management of heparin-induced thrombocytopenia. Current Opinion in Hematology, 2016, 23, 462-470.	1.2	36
214	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. American Journal of Human Genetics, 2018, 103, 144-153.	2.6	36
215	Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Annals of Thoracic Surgery, 2003, 75, 577-579.	0.7	35
216	Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thrombosis Research, 2011, 128, 256-260.	0.8	35

#	Article	IF	Citations
217	The role of social media for blood donor motivation and recruitment. Transfusion, 2018, 58, 2257-2259.	0.8	35
218	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood, 2020, 136, 353-361.	0.6	35
219	Perioperative thrombocytopenia in cardiac surgical patients â€" incidence of heparin-induced thrombocytopenia, morbidities and mortality. European Journal of Cardio-thoracic Surgery, 2010, 37, 1391-1395.	0.6	34
220	Early storage lesions in apheresis platelets are induced by the activation of the integrin Î±IIbÎ²3 and focal adhesion signaling pathways. Journal of Proteomics, 2012, 76, 297-315.	1.2	34
221	Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin. Transfusion, 2014, 54, 640-645.	0.8	34
222	Further insights into the anti-PF4/heparin IgM immune response. Thrombosis and Haemostasis, 2016, 115, 752-761.	1.8	34
223	A population-based longitudinal study on the implications of demographics on future blood supply. Transfusion, 2016, 56, 2986-2994.	0.8	34
224	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	0.6	34
225	Heparin-associated thrombocytopenia: Successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins. Annals of Hematology, 1992, 64, 40-42.	0.8	33
226	Me or not me? The danger of spontaneity. Blood, 2014, 123, 3536-3538.	0.6	33
227	Toward the Relevance of Platelet Subpopulations for Transfusion Medicine. Frontiers in Medicine, 2018, 5, 17.	1.2	33
228	Maternal <scp>HPA</scp>â€1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. Vox Sanguinis, 2019, 114, 79-94.	0.7	33
229	Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany. Lancet Regional Health - Europe, The, 2022, 12, 100270.	3.0	33
230	A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 2001, 85, 950-7.	1.8	33
231	Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrology Dialysis Transplantation, 1997, 12, 2750-2755.	0.4	32
232	Hirudin in Heparin-Induced Thrombocytopenia. Seminars in Thrombosis and Hemostasis, 2002, 28, 431-438.	1.5	32
233	Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics and Genomics, 2003, 13, 253-258.	5.7	32
234	The Use of Direct Thrombin Inhibitors in Cardiovascular Surgery in Patients with Heparin-Induced Thrombocytopenia. Seminars in Thrombosis and Hemostasis, 2004, 30, 315-327.	1.5	32

#	Article	IF	Citations
235	Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates. Transfusion, 2006, 46, 377-385.	0.8	32
236	Expression of ABC-type transport proteins in human platelets. Pharmacogenetics and Genomics, 2010, 20, 396-400.	0.7	32
237	Release of Platelet-Derived Sphingosine-1-Phosphate Involves Multidrug Resistance Protein 4 (MRP4/ABCC4) and Is Inhibited by Statins. Thrombosis and Haemostasis, 2018, 118, 132-142.	1.8	32
238	Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. Expert Review of Hematology, 2008, 1, 75-85.	1.0	31
239	Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Annals of Thoracic Surgery, 2001, 71, 1041-1042.	0.7	30
240	Heparin-Induced Thrombocytopenia in Intensive Care Patients. Seminars in Thrombosis and Hemostasis, 2008, 34, 425-438.	1.5	30
241	Studies of the antiâ€“platelet factor 4/heparin immune response: adapting the enzymeâ€linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion, 2010, 50, 32-39.	0.8	30
242	Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD. Blood, 2012, 119, 3333-3341.	0.6	30
243	Diagnosis of Inherited Platelet Disorders on a Blood Smear. Journal of Clinical Medicine, 2020, 9, 539.	1.0	30
244	Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient. Blood, 2022, 139, 1903-1907.	0.6	30
245	Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT). Seminars in Hematology, 2022, 59, 97-107.	1.8	30
246	Donor Exposures in Recipients of Pooled Platelet Concentrates. New England Journal of Medicine, 2013, 368, 487-489.	13.9	29
247	PDK1 Determines Collagen-Dependent Platelet Ca ²⁺ Signaling and Is Critical to Development of Ischemic Stroke In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1507-1516.	1.1	29
248	Comparative Analysis of a French Prospective Series of 144 Patients with Heparin-Induced Thrombocytopenia (FRIGTIH) and the Literature. Thrombosis and Haemostasis, 2020, 120, 1096-1107.	1.8	29
249	Characterization of New Monoclonal PF4-Specific Antibodies as Useful Tools for Studies on Typical and Autoimmune Heparin-Induced Thrombocytopenia. Thrombosis and Haemostasis, 2021, 121, 322-331.	1.8	29
250	Comparison of HapMap and 1000 Genomes Reference Panels in a Large-Scale Genome-Wide Association Study. PLoS ONE, 2017, 12, e0167742.	1.1	29
251	Erfolgreiche Behandlung einer Heparin-induzierten Thrombo- zytopenie Typ II im Kindesalter mit rekombinantem Hirudin. Monatsschrift Fur Kinderheilkunde, 1997, 145, 606-612.	0.1	28
252	Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia. Thrombosis Research, 2009, 124, 554-559.	0.8	28

#	Article	IF	Citations
253	First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thrombosis and Haemostasis, 1999, 81, 625-9.	1.8	28
254	Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy. Haematologica, 2022, 107, 1219-1221.	1.7	28
255	Evidence that DDAVP transiently improves hemostasis in Bernard-Soulier syndrome independent of von Willebrand-Factor. Annals of Hematology, 1993, 67, 149-150.	0.8	27
256	Cochlear implantation is safe and effective in patients with MYH9-related disease. Orphanet Journal of Rare Diseases, 2014, 9, 100.	1.2	27
257	Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study. Journal of Thrombosis and Thrombolysis, 2015, 39, 60-67.	1.0	27
258	Secreted Immunomodulatory Proteins of Staphylococcus aureus Activate Platelets and Induce Platelet Aggregation. Thrombosis and Haemostasis, 2018, 47, 745-757.	1.8	27
259	Structure and function of the ubiquitinâ€proteasome system in platelets. Journal of Thrombosis and Haemostasis, 2020, 18, 771-780.	1.9	27
260	Heparin-Induced Thrombocytopenia: Frequency and Pathogenesis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 37-45.	0.5	26
261	The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis. Journal of Thrombosis and Haemostasis, 2009, 7, 766-773.	1.9	26
262	Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. American Journal of Human Genetics, 2017, 100, 334-342.	2.6	26
263	Motivational factors for blood donation in firstâ€time donors and repeat donors: a crossâ€sectional study in West Pomerania. Transfusion Medicine, 2017, 27, 413-420.	0.5	26
264	Diagnosis of hereditary platelet disorders in the era of nextâ€generation sequencing: â€œprimum non nocereâ€. Journal of Thrombosis and Haemostasis, 2019, 17, 551-554.	1.9	26
265	Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopeniaâ€”A Case Report. Vaccines, 2021, 9, 1344.	2.1	26
266	Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. American Journal of Hematology, 2005, 78, 188-192.	2.0	25
267	Empfehlungen zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. Transfusion Medicine and Hemotherapy, 2006, 33, 528-543.	0.7	25
268	The adhesion and spreading of thrombocyte vesicles on electrode surfaces. Bioelectrochemistry, 2008, 74, 210-216.	2.4	25
269	Crossreactivity Studies between Sera of Patients with Heparin Associated Thrombocytopenia and a New Low Molecular Weight Heparin, Reviparin. Thrombosis and Haemostasis, 1994, 72, 644-645.	1.8	25
270	Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin). Blood Coagulation and Fibrinolysis, 1998, 9, 273-278.	0.5	24

#	Article	IF	Citations
271	Novel Mutation in Bernard-Soulier Syndrome. Transfusion Medicine and Hemotherapy, 2010, 37, 7-7.	0.7	24
272	Development of a method for magnetic labeling of platelets. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 537-544.	1.7	24
273	Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation. Transfusion, 2012, 52, 529-536.	0.8	24
274	Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial. Critical Care, 2014, 18, 588.	2.5	24
275	Heparin-Induced Thrombocytopenia. BioDrugs, 2000, 14, 109-125.	2.2	23
276	A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia. Transfusion, 2008, 48, 92-98.	0.8	23
277	Postnatal intervention for the treatment of FNAIT: a systematic review. Journal of Perinatology, 2019, 39, 1329-1339.	0.9	23
278	An international external quality assessment for laboratory diagnosis of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 525-531.	1.9	23
279	MYH9 spectrum of autosomal-dominant giant platelet syndromes: Unexpected association with fibulin-1 variant-D inactivation. American Journal of Hematology, 2003, 74, 254-262.	2.0	22
280	So, Does Low-Molecular-Weight Heparin Cause Less Heparin-Induced Thrombocytopenia Than Unfractionated Heparin or Not?. Chest, 2007, 132, 1108-1110.	0.4	22
281	HIT Happens: Diagnosing and Evaluating the Patient with Heparin-Induced Thrombocytopenia. Anesthesia and Analgesia, 2008, 107, 356-358.	1.1	22
282	MYH9 Related Platelet Disorders - Often Unknown and Misdiagnosed. Klinische Padiatrie, 2011, 223, 120-125.	0.2	22
283	Simplifying the diagnosis of inherited platelet disorders? The new tools do not make it any easier. Blood, 2019, 133, 2478-2483.	0.6	22
284	Clinical management, ethics and informed consent related to multiâ€gene panelâ€based high throughput sequencing testing for platelet disorders: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 2751-2758.	1.9	22
285	Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro. Blood Advances, 2020, 4, 6315-6326.	2.5	22
286	Low-dose danaparoid sodium catheter flushes in an intensive care infant suffering from heparin-induced thrombocytopenia. Pediatric Critical Care Medicine, 2001, 2, 175-177.	0.2	21
287	Thrombosis of the Cerebral Veins and Sinuses. New England Journal of Medicine, 2005, 353, 314-315.	13.9	21
288	Contaminated Heparin. New England Journal of Medicine, 2008, 359, 1291-1293.	13.9	21

#	Article	IF	Citations
289	Platelet activation by heparin. Blood, 2011, 117, 4686-4687.	0.6	21
290	Reduced platelet forces underlie impaired hemostasis in mouse models of MYH9 -related disease. Science Advances, 2022, 8, eabn2627.	4.7	21
291	Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia. Thrombosis Research, 2012, 129, 465-469.	0.8	20
292	Defective Zn2+ homeostasis in mouse and human platelets with Î±- and Î´-storage pool diseases. Scientific Reports, 2019, 9, 8333.	1.6	20
293	Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 3193-3202.	1.9	20
294	Successful Thrombolysis of Right Atrial and Ventricle Thrombi Encircling a Temporary Pacemaker Lead in a Patient with Heparin-Induced Thrombocytopenia Type II. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 678-681.	0.5	19
295	Drugs for the Prevention and Treatment of Thrombosis in Patients with Heparin-Induced Thrombocytopenia. American Journal of Cardiovascular Drugs, 2001, 1, 429-443.	1.0	19
296	Magnetic Nanoparticle Labeling of Human Platelets from Platelet Concentrates for Recovery and Survival Studies. ACS Applied Materials & Interfaces, 2017, 9, 34666-34673.	4.0	19
297	Quantifying singleâ€platelet biomechanics: An outsiderâ€™s guide to biophysical methods and recent advances. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 386-401.	1.0	19
298	Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome). European Journal of Haematology, 2007, 79, 263-268.	1.1	18
299	Epitope mapping of antibodies directed against the human neutrophil alloantigen 3a. Transfusion, 2011, 51, 2160-2167.	0.8	18
300	Heparin-induced thrombocytopenia: further evidence for a unique immune response. Blood, 2012, 120, 4238-4245.	0.6	18
301	Platelet factor 4/heparin complexes present epitopes differently on solid-phase vs platelet surfaces. Blood, 2017, 129, 3498-3501.	0.6	18
302	Foudroyant cerebral venous (sinus) thrombosis triggered through CLEC-2 and GPIIb/IIIa dependent platelet activation. , 2022, 1, 132-141.		18
303	Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation--a possible new indication for high dose i.v. IgG. Thrombosis and Haemostasis, 1994, 71, 641-5.	1.8	18
304	Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin. Journal of Thrombosis and Thrombolysis, 2000, 10, 47-57.	1.0	17
305	A patient with Fechtner syndrome successfully treated with romiplostim. Thrombosis and Haemostasis, 2012, 107, 590-591.	1.8	17
306	Effect of pH and ionic strength on the binding strength of anti-PF4/polyanion antibodies. European Biophysics Journal, 2017, 46, 795-801.	1.2	17

#	Article	IF	Citations
307	Mean platelet volume is more important than age for defining reference intervals of platelet counts. PLoS ONE, 2019, 14, e0213658.	1.1	17
308	Evaluation of functional assays for the diagnosis of heparin induced thrombocytopenia using 5B9, a monoclonal IgG that mimics human antibodies. Journal of Thrombosis and Haemostasis, 2020, 18, 968-975.	1.9	17
309	Laboratory Testing for Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 227-260.	0.0	17
310	Heparinâ€Associated Thrombocytopenia: No Association of Immune Response with HLA. Vox Sanguinis, 1993, 65, 151-153.	0.7	16
311	Subfractionation and purification of intracellular granule-structures of human platelets: An improved method based on magnetic sorting. Journal of Immunological Methods, 2007, 328, 89-96.	0.6	16
312	Biophysical tools to assess the interaction of PF4 with polyanions. Thrombosis and Haemostasis, 2016, 116, 783-791.	1.8	16
313	Recessive grey platelet-like syndrome with unaffected erythropoiesis in the absence of the splice isoform GFI1B-p37. Haematologica, 2017, 102, e375-e378.	1.7	16
314	Label-free on chip quality assessment of cellular blood products using real-time deformability cytometry. Lab on A Chip, 2020, 20, 2306-2316.	3.1	16
315	Platelet response to vascular surgeryâ€"A preliminary study on the effect of aspirin and heparin. Thrombosis Research, 1994, 76, 79-87.	0.8	15
316	Transfusion Medicine in the Era of Genomics and Proteomics. Transfusion Medicine Reviews, 2005, 19, 288-294.	0.9	15
317	Very severe thrombocytopenia and fragmentation hemolysis mimicking thrombotic thrombocytopenic purpura associated with a giant intracardiac vegetation infected withStaphylococcus epidermidis: Role of monocyte procoagulant activity induced by bacterial supernatant. American Journal of Hematology, 2007, 82, 766-771.	2.0	15
318	Expression of the <scp>CTL</scp>2 transcript variants in human peripheral blood cells and human tissues. Transfusion, 2013, 53, 3217-3223.	0.8	15
319	Characterization of bonds formed between platelet factor 4 and negatively charged drugs using single molecule force spectroscopy. Soft Matter, 2014, 10, 2775.	1.2	15
320	Longitudinal Changes in the Blood Supply and Demand in North-East-Germany 2005-2015. Transfusion Medicine and Hemotherapy, 2017, 44, 224-231.	0.7	15
321	Platelet Transfusion in Perioperative Medicine. Seminars in Thrombosis and Hemostasis, 2020, 46, 050-061.	1.5	15
322	Acquired Hemophilia With Inhibitors Presenting as an Emergency. Deutsches Ärzteblatt International, 2014, 111, 345-8.	0.6	15
323	Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease: successful anticoagulation with the low-molecular-weight heparinoid Org 10172 during haemodialysis. Nephrology Dialysis Transplantation, 1993, 8, 1176-7.	0.4	15
324	Immunogenic but effective: the HIT-fondaparinux brain puzzler. Journal of Thrombosis and Haemostasis, 2011, 9, 2386-2388.	1.9	14

#	Article	IF	Citations
325	Altered timing of riboflavin and ultraviolet light pathogen inactivation improves platelet in vitro quality. Transfusion, 2017, 57, 2026-2034.	0.8	14
326	Not all red cell concentrate units are equivalent: international survey of processing and in vitro quality data. Vox Sanguinis, 2019, 114, 783-794.	0.7	14
327	Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. Blood, 2019, 133, 978-989.	0.6	14
328	Heparinâ€induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation. Journal of Thrombosis and Haemostasis, 2021, 19, 1959-1972.	1.9	14
329	Heparin-induced thrombocytopenia. Hamostaseologie, 2010, 30, 17-8, 20-8.	0.9	14
330	May-Hegglin anomaly: A rare cause of thrombocytopenia. European Journal of Pediatrics, 1992, 151, 668-671.	1.3	13
331	Angiotensin II-dependent hypertension causes reversible changes in the platelet proteome. Journal of Hypertension, 2011, 29, 2126-2137.	0.3	13
332	Micropatterned array to assess the interaction of single platelets with platelet factor 4-heparin-IgG complexes. Thrombosis and Haemostasis, 2014, 111, 862-872.	1.8	13
333	ABO blood type B and fucosyltransferase 2 non-secretor status as genetic risk factors for chronic pancreatitis. Gut, 2016, 65, 353-354.	6.1	13
334	Distinct Binding Characteristics of Pathogenic Anti-Platelet Factor-4/Polyanion Antibodies to Antigens Coated on Different Substrates: A Perspective on Clinical Application. ACS Nano, 2018, 12, 12030-12041.	7.3	13
335	Activated platelets kill Staphylococcus aureus, but not Streptococcus pneumoniaeâ€"The role of FcÎ³RIIa and platelet factor 4/heparinantibodies. Journal of Thrombosis and Haemostasis, 2020, 18, 1459-1468.	1.9	13
336	Heparin-induced thrombocytopenia (HIT): in vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin). European Journal of Haematology, 2000, 65, 148-149.	1.1	12
337	Management of liver transplantation in a patient with a history of heparin-induced thrombocytopenia. Transplant International, 2005, 18, 664-667.	0.8	12
338	The Diagnostic Value of the Anti-PF4/Heparin Immunoassay High-Dose Heparin Confirmatory Test in Cardiac Surgery Patients. Anesthesia and Analgesia, 2011, 112, 774-776.	1.1	12
339	The molecular charge and size of heparins determine their impact on the decidualization of human endometrial stromal cells. Molecular Human Reproduction, 2011, 17, 354-359.	1.3	12
340	Several adaptor proteins promote intracellular localisation of the transporter MRP4/ABCC4 in platelets and haematopoietic cells. Thrombosis and Haemostasis, 2017, 117, 105-115.	1.8	12
341	Outcome of an enhanced diagnostic pipeline for patients suspected of inherited thrombocytopenia. British Journal of Haematology, 2019, 186, 373-376.	1.2	12
342	The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2020, 1868, 140281.	1.1	12

#	Article	IF	Citations
343	Characterization of the interaction between platelet factor 4 and homogeneous synthetic low molecular weight heparins. Journal of Thrombosis and Haemostasis, 2020, 18, 390-398.	1.9	12
344	Proteomics: A Tool to Study Platelet Function. International Journal of Molecular Sciences, 2021, 22, 4776.	1.8	12
345	Severe Hemorrhage Associated With Oral Anticoagulants. Deutsches Ärzteblatt International, 2020, 117, 312-319.	0.6	12
346	Longitudinal Aspects of VITT. Seminars in Hematology, 2022, 59, 108-114.	1.8	12
347	Diagnosis and management of heparin-induced thrombocytopenia. Canadian Journal of Anaesthesia, 2006, 53, S123-S134.	0.7	11
348	Management of heparin-induced thrombocytopenia. Expert Opinion on Pharmacotherapy, 2012, 13, 987-1006.	0.9	11
349	The transfusionâ€related acute lung injury controversy: lessons from heparinâ€induced thrombocytopenia. Transfusion, 2015, 55, 1128-1134.	0.8	11
350	Novel phenotypes observed in patients with ETV6-linked leukaemia/familial thrombocytopenia syndrome and a biallelic ARID5B risk allele as leukaemogenic cofactor. Journal of Medical Genetics, 2020, 57, 427-433.	1.5	11
351	Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome. Blood Advances, 2020, 4, 3368-3377.	2.5	11
352	Ticagrelor causes false-negative functional tests for heparin-induced thrombocytopenia. Blood, 2020, 135, 875-878.	0.6	11
353	Characterization of 5B9, a Chimeric Monoclonal Anti-PF4/H Antibody with a Human Fc Fragment and Which Mimics the Effects of HIT Human Antibodies. Blood, 2016, 128, 138-138.	0.6	11
354	Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2. Thrombosis and Haemostasis, 2022, 122, 304-307.	1.8	11
355	Laboratory testing for VITT antibodies. Seminars in Hematology, 2022, 59, 80-88.	1.8	11
356	Recombinant hirudin is a heparin alternative in cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia, 1997, 11, 538-539.	0.6	10
357	Glucosamine sulfate does not crossreact â€¨with the antibodies of patients with â€¨heparin-induced thrombocytopenia. European Journal of Haematology, 2001, 66, 195-199.	1.1	10
358	Treatment options for heparin-induced thrombocytopenia. American Journal of Health-System Pharmacy, 2003, 60, S12-S18.	0.5	10
359	Potassium â€“ reference intervals for lithium-heparin plasma and serum from a population-based cohort / Kalium â€“ Referenzbereiche fÃ¼r Lithium-Heparin-Plasma und Serum aus einer bevÃ¶lkerungsbezogenen Studie. Laboratoriums Medizin, 2010, 34, 39-44.	0.1	10
360	Pooled Platelet Concentrates or Apheresis Platelets?. New England Journal of Medicine, 2013, 368, 1848-1849.	13.9	10

#	Article	IF	Citations
361	Uptake Pathways of Protein-Coated Magnetic Nanoparticles in Platelets. ACS Applied Materials & Interfaces, 2018, 10, 28314-28321.	4.0	10
362	GPVI expression is linked to platelet size, age, and reactivity. Blood Advances, 2022, 6, 4162-4173.	2.5	10
363	A variant of the Sebastian platelet syndrome with unique neutrophil inclusions. Platelets, 2002, 13, 121-127.	1.1	9
364	Antiâ€platelet factor 4/heparin antibodies in patients with impaired graft function after liver transplantation. Journal of Thrombosis and Haemostasis, 2014, 12, 871-878.	1.9	9
365	Assessment of human platelet survival in the NOD/SCID mouse model: technical considerations. Transfusion, 2016, 56, 1370-1376.	0.8	9
366	Interaction between the Staphylococcus aureus extracellular adherence protein Eap and its subdomains with platelets. International Journal of Medical Microbiology, 2018, 308, 683-691.	1.5	9
367	Response of Human Blood Platelets on Nanoscale Groove Patterns: Implications for Platelet Storage. ACS Applied Nano Materials, 2020, 3, 6996-7004.	2.4	9
368	Anticoagulation in COVID-19: not strong for too long?. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100857.	0.6	9
369	Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels. Haematologica, 2021, 106, 3249-3252.	1.7	9
370	Treatment of heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 1999, 82, 457-67.	1.8	9
371	ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. Blood, 2022, 140, 274-284.	0.6	9
372	Too many hits in HIT?. American Journal of Hematology, 2007, 82, 1035-1036.	2.0	8
373	Opposites attract. Blood, 2010, 115, 440-441.	0.6	8
374	Coombsâ€™ crossmatch after negative antibody screening - a retrospective observational study comparing the tube test and the microcolumn technology. Vox Sanguinis, 2010, 98, e269-e275.	0.7	8
375	Evaluation of a <scp>N</scp>ew <scp>G</scp>erman blood donor questionnaire. Vox Sanguinis, 2014, 106, 55-60.	0.7	8
376	Impact of priming on the response of neutrophils to human neutrophil alloantigenâ€3a antibodies. Transfusion, 2015, 55, 1512-1521.	0.8	8
377	Function of Large and Small Platelets Differs, Depending on Extracellular Calcium Availability and Type of Inductor. Thrombosis and Haemostasis, 2020, 120, 1075-1086.	1.8	8
378	Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. Thrombosis and Haemostasis, 2022, 122, 552-559.	1.8	8

#	Article	IF	Citations
379	Vaccineâ€induced immune thrombotic thrombocytopenia (VITT) â€•update on diagnosis and management considering different resources: Response to Comment from Yamada et al. Journal of Thrombosis and Haemostasis, 2022, 20, 542-543.	1.9	8
380	Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway. European Heart Journal Open, 2022, 2, .	0.9	8
381	13 Heparin-induced thrombocytopenia: pathophysiology and clinical concerns. Best Practice and Research: Clinical Haematology, 1998, 11, 461-474.	1.1	7
382	Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?. European Journal of Haematology, 2007, 79, 187-190.	1.1	7
383	Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantationâ€"a matched pair analysis. Annals of Hematology, 2013, 92, 945-952.	0.8	7
384	Comparison of the 99th percentiles of three troponin I assays in a large reference population. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2181-6.	1.4	7
385	Mass spectrometric phosphoproteome analysis of small-sized samples of human neutrophils. Clinica Chimica Acta, 2015, 451, 199-207.	0.5	7
386	Reactivity of plateletâ€activating and nonplateletâ€activating antiâ€PF4/heparin antibodies in enzyme immunosorbent assays under different conditions. Journal of Thrombosis and Haemostasis, 2019, 17, 1113-1119.	1.9	7
387	Physicochemical Characteristics of Platelet Factor 4 under Various Conditions are Relevant for Heparin-Induced Thrombocytopenia Testing. Journal of Physical Chemistry B, 2020, 124, 1438-1443.	1.2	7
388	Effect of Methylene Blue Pathogen Inactivation on the Integrity of Immunoglobulin M and G. Transfusion Medicine and Hemotherapy, 2021, 48, 148-153.	0.7	7
389	Functional Flow Cytometric Assay for Reliable and Convenient Heparin-Induced Thrombocytopenia Diagnosis in Daily Practice. Biomedicines, 2021, 9, 332.	1.4	7
390	Thrombin generation, ProC(Â®)Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation. Blood Transfusion, 2016, 14, 66-72.	0.3	7
391	The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies. Haematologica, 2022, 107, 2445-2453.	1.7	7
392	Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. Blood Advances, 2022, 6, 4137-4146.	2.5	7
393	SARS-CoV-2 Infection in Patients with a History of VITT. New England Journal of Medicine, 2022, 387, 88-90.	13.9	7
394	Heparininduzierte Thrombozytopenie in der Pï¿½diatrie und ihre Therapiealternativen. Monatsschrift Fur Kinderheilkunde, 2003, 151, 1180-1187.	0.1	6
395	Unfractionated LMWH and the risk of HIT: are medical patients different?. Blood, 2005, 106, 2931-2932.	0.6	6
396	Isolation of Platelet Granules. Current Protocols in Cell Biology, 2010, 46, Unit 3.35.	2.3	6

#	Article	IF	Citations
397	Proteomic profile of platelets during reconstitution of platelet counts after apheresis. Proteomics - Clinical Applications, 2016, 10, 831-838.	0.8	6
398	The 99th percentile and imprecision of point-of-care cardiac troponin I in comparison to central laboratory tests in a large reference population. Clinical Biochemistry, 2017, 50, 1198-1202.	0.8	6
399	Wellâ€being and return rate of firstâ€time whole blood donors. Vox Sanguinis, 2019, 114, 154-161.	0.7	6
400	Transfusion in limited infrastructure locations â€“ where to go decades after safe blood initiative by World Health Organization?. ISBT Science Series, 2020, 15, 118-125.	1.1	6
401	Characterization of the Human Neutrophil Alloantigen (HNA) 3a.. Blood, 2009, 114, 24-24.	0.6	6
402	Treatment of Heparin-Induced ÂThrombocytopenia: An Overview. Fundamental and Clinical Cardiology, 2007, , 283-318.	0.0	6
403	GFHT proposals on the practical use of argatroban â€" With specifics regarding vaccine-induced immune thrombotic thrombocytopaenia (VITT). Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100963.	0.6	6
404	Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF4/heparin-antibody test. Upsala Journal of Medical Sciences, 2013, 118, 279-284.	0.4	5
405	Human neutrophil antigenâ€3a antibodies induce neutrophil stiffening and conformational activation of CD11b without shedding of Lâ€selectin. Transfusion, 2015, 55, 2939-2948.	0.8	5
406	Heparin-induced thrombocytopenia in 2017 and beyond. Thrombosis and Haemostasis, 2016, 116, 781-782.	1.8	5
407	Reversal of dabigatran by idarucizumab: when and how?. Expert Review of Hematology, 2016, 9, 519-528.	1.0	5
408	Impact of physical activity of individuals and creatine kinase on 99th percentiles of troponin I assays. Clinica Chimica Acta, 2016, 462, 187-192.	0.5	5
409	Real-life evaluation of an automated immunoassay for diagnosis of heparin-induced thrombocytopenia. Thrombosis Research, 2020, 196, 400-403.	0.8	5
410	Characteristics of Recipients of Red Blood Cell Concentrates in a German Federal State. Transfusion Medicine and Hemotherapy, 2020, 47, 370-378.	0.7	5
411	Blood Product Supply for a Helicopter Emergency Medical Service. Transfusion Medicine and Hemotherapy, 2021, 48, 332-341.	0.7	5
412	Multicentre evaluation of 5B9, a monoclonal antiâ€PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal of Thrombosis and Haemostasis, 2022, 20, 252-259.	1.9	5
413	The Deglycosylated Form of 1E12, a Monoclonal Anti-PF4 IgG, Strongly Inhibits Antibody-Triggered Cellular Activation in Vaccine-Induced Thrombotic Thrombocytopenia, and Is a Potential New Treatment for VÎ¹Ï„Ï„. Blood, 2021, 138, 582-582.	0.6	5
414	The COVIDâ€19 vaccine ChAdOx1â€S is not contaminated with sulfated glycosaminoglycans. Journal of Thrombosis and Haemostasis, 2022, 20, 777-780.	1.9	5

#	Article	IF	Citations
415	Ex vivo anticoagulants affect human blood platelet biomechanics with implications for high-throughput functional mechanophenotyping. Communications Biology, 2022, 5, 86.	2.0	5
416	Î±â€hemolysin of Staphylococcus aureus impairs thrombus formation. Journal of Thrombosis and Haemostasis, 2022, 20, 1464-1475.	1.9	5
417	Immune mechanisms in heparinâ€induced thrombocytopenia: no evidence for immunoglobulin M antiâ€idiotype antibodies. Transfusion, 2009, 49, 1812-1818.	0.8	4
418	HIT-antibodies promote their own antigen. Blood, 2012, 120, 930-931.	0.6	4
419	New insights in heparin-induced thrombocytopenia by the use of fluid-phase assays to detect specifically platelet factor 4/heparin complex antibodies and antibody-secreting cells. Thrombosis Research, 2014, 134, 174-181.	0.8	4
420	Another surprising finding in heparin-induced thrombocytopenia - eat big. Journal of Thrombosis and Haemostasis, 2015, 13, 1414-1415.	1.9	4
421	Partially desulfated heparin modulates the interaction between anti-protamine/heparin antibodies and platelets. Thrombosis and Haemostasis, 2016, 115, 324-332.	1.8	4
422	Thrombin generation in two families with MYH9-related platelet disorder. Platelets, 2016, 27, 264-267.	1.1	4
423	Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1091-1097.	1.2	4
424	In the Mood for a Blood Donation? Pilot Study about Momentary Mood, Satisfaction, and Return Behavior in Deferred First-Time Donors. Transfusion Medicine and Hemotherapy, 2021, 48, 220-227.	0.7	4
425	Role of Sulfated Polysaccharides in the Pathogenesis?of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 167-186.	0.0	4
426	Human neutrophil antigen-3a antibodies induce neutrophil aggregation in a plasma-free medium. Blood Transfusion, 2013, 11, 541-7.	0.3	4
427	Polyvalent Immunoglobulin Preparations Inhibit Pneumolysin-Induced Platelet Destruction. Thrombosis and Haemostasis, 2021, , .	1.8	4
428	Iron deficiency anaemia in young women . A hypothesis on the impact of the platelet collagen receptor GPIaIIa polymorphism GPIa-C807T. European Journal of Haematology, 2002, 68, 341-344.	1.1	3
429	Heparin-Induced Thrombocytopenia. Methods in Molecular Biology, 2013, 992, 301-318.	0.4	3
430	Tranexamic acid for treatment of bleeding in hemophagocytic lymphohistiocytosis. Thrombosis Research, 2015, 135, 1037-1039.	0.8	3
431	Flucloxacillinâ€induced immune thrombocytopenia. Transfusion, 2016, 56, 67-72.	0.8	3
432	High-Sensitivity Cardiac Troponin T: Association of Creatine Kinase Catalytic Activity With the 99th Percentile. Clinical Chemistry, 2018, 64, 973-974.	1.5	3

#	Article	IF	Citations
433	Prospective evaluation of two specific IgG immunoassays (HemosIL^{Â®} AcuStar HITâ€IgG and) Tj ETQq1 1 0.784314 rgBT /O International Journal of Laboratory Hematology, 2021, 43, 468-476.	0.7	3
434	The EHA Research Roadmap: Platelet Disorders. HemaSphere, 2021, 5, e601.	1.2	3
435	Diagnosing Inherited Platelet Disorders: Modalities and Consequences. Hamostaseologie, 2021, 41, 475-488.	0.9	3
436	Population-Based Analysis of the Impact of Demographics on the Current and Future Blood Supply in the Saarland. Transfusion Medicine and Hemotherapy, 2021, 48, 175-182.	0.7	3
437	Transfusion medicine and proteomics. Alliance or coexistence?. Blood Transfusion, 2010, 8 Suppl 3, s16-25.	0.3	3
438	Hemostatic management of patients undergoing ear-nose-throat surgery. GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery, 2015, 14, Doc07.	0.8	3
439	Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease. Blood Advances, 2022, 6, 5244-5255.	2.5	3
440	Cytoskeleton Dependent Mobility Dynamics of FcÎ³RIIA Facilitates Platelet Haptotaxis and Capture of Opsonized Bacteria. Cells, 2022, 11, 1615.	1.8	3
441	Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry. Neurological Research and Practice, 2022, 4, 16.	1.0	3
442	Postoperative Complications After Cardiac Surgery and HIT: A Word of Caution. Annals of Thoracic Surgery, 2008, 86, 1054-1055.	0.7	2
443	Heparin/PF4 antibodies formation after heparin treatment: Temporal aspects and long-term follow-upâ€"Letter to the Editor. American Heart Journal, 2009, 158, e15.	1.2	2
444	Advances in the treatment of heparin-induced thrombocytopenia: latest clinical data. Clinical Investigation, 2011, 1, 1301-1314.	0.0	2
445	Why has the demand for platelet components increased? A commentary. Transfusion Medicine, 2014, 24, 257-259.	0.5	2
446	Why is one arm stronger than two arms? IgG4 antibodies in IgG4-related autoimmune pancreatitis. Gut, 2016, 65, 1240-1241.	6.1	2
447	Platelets modulate T-cell activity. Blood, 2021, 138, 358-360.	0.6	2
448	The platelet proteasome and immunoproteasome are stable in buffyâ€coat derived platelet concentrates for up to 7â€‰days. Transfusion, 2021, 61, 2746-2755.	0.8	2
449	International Validation of a Dithiothreitol (DTT)-Based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing. Blood, 2015, 126, 3567-3567.	0.6	2
450	Lepirudin for the Treatment of Heparin-Âinduced?Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 345-378.	0.0	2

#	Article	IF	Citations
451	10 Years of Experience with the First Thawed Plasma Bank in Germany. Transfusion Medicine and Hemotherapy, 2021, 48, 350-357.	0.7	2
452	The îœ€2 Gene Coding Sequence T807/A873 of the Platelet Collagen Receptor Integrin îœ€2Î²1 Might Be a Genetic Risk Factor for the Development of Stroke in Younger Patients. Blood, 1999, 93, 3583-3586.	0.6	2
453	Divalent magnesium restores cytoskeletal storage lesions in cold-stored platelet concentrates. Scientific Reports, 2022, 12, 6229.	1.6	2
454	Heparin-induced thrombocytopenia with a focus on children undergoing cardiac surgery. Progress in Pediatric Cardiology, 2005, 21, 71-79.	0.2	1
455	Taking advantage of the non-anticoagulant effects of heparin. Thrombosis and Haemostasis, 2012, 107, 602.	1.8	1
456	<scp>HNA</scp> antibodyâ€mediated neutrophil aggregation is dependent on serine protease activity. Vox Sanguinis, 2015, 109, 366-374.	0.7	1
457	Predonation finger lancet punctures: a potential risk factorÂfor interdonor pathogen transmission in the bloodÂdonor clinic. Vox Sanguinis, 2016, 111, 3-7.	0.7	1
458	Implementation of a rapid HIT immunoassay at a university hospital â€“ Retrospective analysis of HIT laboratory orders in patients with thrombocytopenia. Thrombosis Research, 2017, 158, 65-70.	0.8	1
459	Idiopathic catastrophic thrombosis with happy ending. BMJ Case Reports, 2017, 2017, bcr-2017-221194.	0.2	1
460	Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?. Transfusion Medicine Reviews, 2020, 34, 128-129.	0.9	1
461	Highly impaired platelet ultrastructure in two families with novel IKZF5 variants. Platelets, 2021, 32, 492-497.	1.1	1
462	A Cross-Sectional Study of Blood Donorsâ€™ Psychological Characteristics over 8 Weeks. Transfusion Medicine and Hemotherapy, 2022, 49, 67-75.	0.7	1
463	An Autosomal-Recessive GFI1B Mutation Defines the Splice Isoform p37 As Essential for Biogenesis of Functional Human Platelets, but Dispensable for Erythropoiesis. Blood, 2016, 128, 2644-2644.	0.6	1
464	Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood, 2000, 96, 2373-2378.	0.6	1
465	Therapie mit Antikoagulanzien, Thrombozytenfunktionshemmern und Thrombolytika. Springer-Lehrbuch, 2010, , 105-120.	0.1	1
466	Group B Streptococcal Hemolytic Pigment Impairs Platelet Function in a Two-Step Process. Cells, 2022, 11, 1637.	1.8	1
467	Bacteria and HIT: a close connection?. Blood, 2011, 117, 1105-1106.	0.6	0
468	Hospital-specific calculation of heparin-induced thrombocytopenia costs: a review/Kalkulation der Kosten fÃ¼r eine Heparin-induzierte Thrombozytopenie (HIT) in KrankenhaÃ¼sern. Laboratoriums Medizin, 2011, 35, 35-43.	0.1	0

#	Article	IF	Citations
469	Development of <scp>RBC</scp> transfusion indications and the collection of patientâ€specific preâ€transfusion information. Vox Sanguinis, 2017, 112, e22-e47.	0.7	0
470	12. GerinnungsstÃ¶rungen im Rahmen des SHT. , 2018, , 209-220.		0
471	International Forum on typing and matching strategies in patients on antiâ€<scp>CD</scp>38 monoclonal therapy. Vox Sanguinis, 2018, 113, e36.	0.7	0
472	An interdisciplinary approach to diagnose and manage Heparin-induced Thrombocytopenia. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 197-198.	0.6	0
473	A novel homozygous GFI1B variant in 2 sisters with thrombocytopenia and severe bleeding tendency. Platelets, 2021, 32, 701-704.	1.1	0
474	Response. Chest, 2021, 160, e95-e96.	0.4	0
475	Response. Chest, 2021, 160, e250.	0.4	0
476	Acute myocardial infarction and arterial embolism in a patient with newly diagnosed renal mass: management dilemmas! A case report. BMC Urology, 2021, 21, 111.	0.6	0
477	Heparin-Induced Thrombocytopenia in Children. Fundamental and Clinical Cardiology, 2007, , 503-518.	0.0	0
478	Adenosine Diphosphate (ADP) and ADP Receptor Play a Major Role in Platelet Activation/Aggregation Induced by Sera From Heparin-Induced Thrombocytopenia Patients. Blood, 1998, 91, 549-554.	0.6	0
479	In Reply. Deutsches Ärzteblatt International, 2015, 112, 506.	0.6	0
480	Acquired Thrombocytopenia. , 2016, , 327-349.		0
481	Interventional Endoscopyâ€" Opportunities and Limitations. Deutsches Ärzteblatt International, 2016, 113, 119-20.	0.6	0
482	In Reply. Deutsches Ärzteblatt International, 2020, 117, 753.	0.6	0
483	Plasma Isoagglutinin Depletion for Blood Group Independent Plasma Transfusion. Transfusion Medicine and Hemotherapy, 0, , 1-7.	0.7	0
484	Risk of Blood Bag Lesions Induced by Standard Transfusion Devices. Transfusion Medicine and Hemotherapy, 0, , 1-2.	0.7	0